ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Real-world durability of faricimab in treatment-naïve nAMD patients: outcomes of an observe-and-plan regimen.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the long-term durability and treatment-free intervals of treatment-naïve patients with neovascular age-related macular degeneration (nAMD) treated with faricimab under an observe-and-plan (O&P) regimen in a real-world setting.
methodsThis retrospective, single-center cohort study included 410 treatment-naïve eyes with active nAMD. All eyes received an initial loading phase consisting of three monthly intravitreal injections of faricimab. At the first post-loading visit, patients were assigned to either the "pause group" or the "continue group" based on the presence of a dry macula. The primary outcomes included changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and treatment-free interval duration.
resultsPost-loading, mean BCVA improved by + 3.6 letters (p < 0.001) while mean CRT decreased by 122.8 μm (p < 0.001). Overall, 68.5% of eyes (n = 281) achieved a dry macula and transitioned to the pause group. Within this group, the median treatment-free interval was 6.0 months (mean 7.1 ± 4.6 months), with 18.1% of patients remaining stable for > 52 weeks without the need for re-treatment. Baseline CRT was identified as a significant predictor of treatment extension. It was found to be significantly higher in the "continue group" than in the "pause group" (449.2 ± 148.9 vs. 403.8 ± 118.0 μm; p < 0.001). Age, sex, and baseline BCVA did not affect the duration of the treatment-free interval.
conclusionsFaricimab demonstrates strong real-world efficacy, enabling immediate extension of treatment intervals under an O&P regimen. Baseline CRT is an important anatomical biomarker that helps tailor treatment regimens to individuals and reduce treatment burden.
Indexed as
Identifiers
42834106What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.